Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
New York State Psychiatric Institute
Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear reactivation procedure. Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Principal Diagnosis of Obsessive-Compulsive Disorder
You may not be if
History of other serious psychiatric disorder
Current Major Depressive Disorder
Women who are pregnant or nursing
Current use of psychiatric medication
Persons planning to start another treatment during the study period
Any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol
